Earlier this year, UCL licensed a gene therapy programme for haemophilia A to BioMarin Pharmaceuticals. As a result, the treatment will get access to the marketplace, and UCL will receive funds from any profits, that it will then plough back into research. Such collaboration offers a win-win scenario for all involved.
Read: CityAM
Close
